<!DOCTYPE html>
<html prefix='og: http://ogp.me/ns#'>
<head>
<link href='../favicon.png' rel='icon' type='image/png'>
<link href='../assets/apple-touch-icon.png' rel='apple-touch-icon' sizes='72x72' type='image/png'>
<link href='pd-1.html' rel='canonical'>
<meta content='text/html;charset=utf-8' http-equiv='Content-Type'>
<meta content='IE=edge,chrome=1' http-equiv='X-UA-Compatible'>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-6.newrelic.com","errorBeacon":"bam.nr-data.net","licenseKey":"df7d6b7270","applicationID":"3316025","transactionName":"cl5cF0cLWlsDEEsHWF9FVw1BS0VfCRU=","queueTime":0,"applicationTime":461,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-515.min.js"}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function(n,t,e){function r(e){if(!t[e]){var o=t[e]={exports:{}};n[e][0].call(o.exports,function(t){var o=n[e][1][t];return r(o?o:t)},o,o.exports)}return t[e].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<e.length;o++)r(e[o]);return r}({QJf3ax:[function(n,t){function e(n){function t(t,e,a){n&&n(t,e,a),a||(a={});for(var u=c(t),f=u.length,s=i(a,o,r),p=0;f>p;p++)u[p].apply(s,e);return s}function a(n,t){f[n]=c(n).concat(t)}function c(n){return f[n]||[]}function u(){return e(t)}var f={};return{on:a,emit:t,create:u,listeners:c,_events:f}}function r(){return{}}var o="nr@context",i=n("gos");t.exports=e()},{gos:"7eSDFh"}],ee:[function(n,t){t.exports=n("QJf3ax")},{}],gos:[function(n,t){t.exports=n("7eSDFh")},{}],"7eSDFh":[function(n,t){function e(n,t,e){if(r.call(n,t))return n[t];var o=e();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(n,t,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return n[t]=o,o}var r=Object.prototype.hasOwnProperty;t.exports=e},{}],D5DuLP:[function(n,t){function e(n,t,e){return r.listeners(n).length?r.emit(n,t,e):(o[n]||(o[n]=[]),void o[n].push(t))}var r=n("ee").create(),o={};t.exports=e,e.ee=r,r.q=o},{ee:"QJf3ax"}],handle:[function(n,t){t.exports=n("D5DuLP")},{}],XL7HBI:[function(n,t){function e(n){var t=typeof n;return!n||"object"!==t&&"function"!==t?-1:n===window?0:i(n,o,function(){return r++})}var r=1,o="nr@id",i=n("gos");t.exports=e},{gos:"7eSDFh"}],id:[function(n,t){t.exports=n("XL7HBI")},{}],loader:[function(n,t){t.exports=n("G9z0Bl")},{}],G9z0Bl:[function(n,t){function e(){var n=v.info=NREUM.info;if(n&&n.licenseKey&&n.applicationID&&f&&f.body){c(d,function(t,e){t in n||(n[t]=e)}),v.proto="https"===l.split(":")[0]||n.sslForHttp?"https://":"http://",a("mark",["onload",i()]);var t=f.createElement("script");t.src=v.proto+n.agent,f.body.appendChild(t)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=n("handle"),c=n(1),u=window,f=u.document,s="addEventListener",p="attachEvent",l=(""+location).split("?")[0],d={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-515.min.js"},v=t.exports={offset:i(),origin:l,features:{}};f[s]?(f[s]("DOMContentLoaded",o,!1),u[s]("load",e,!1)):(f[p]("onreadystatechange",r),u[p]("onload",e)),a("mark",["firstbyte",i()])},{1:11,handle:"D5DuLP"}],11:[function(n,t){function e(n,t){var e=[],o="",i=0;for(o in n)r.call(n,o)&&(e[i]=t(o,n[o]),i+=1);return e}var r=Object.prototype.hasOwnProperty;t.exports=e},{}]},{},["G9z0Bl"]);</script>
<meta content='ycLJxifWV5TMCaeBV4zy1XzXAlxSn13YlTqZjZ4_GeQ' name='google-site-verification'>
<!-- / OG and Twitter Card meta data tags -->
<meta content="Patients and caregivers discuss drugs that target PD-1: clinical trials, research results, and more." property="og:description" />
<meta content="Patients and caregivers discuss drugs that target PD-1: clinical trials, research results, and more." property="twitter:description" />
<meta content="PD-1 Community" property="og:title" />
<meta content="PD-1 Community" property="twitter:title" />
<meta content="https://www.smartpatients.com/pathways/pd-1" property="og:url" />
<meta content="https://www.smartpatients.com/pathways/pd-1" property="twitter:url" />
<meta content="article" property="og:type" />
<meta content="article" property="twitter:type" />
<meta content="https://www.smartpatients.com/smart-patients-logo-200.png" property="og:image" />
<meta content="summary" property="twitter:card" />
<meta content="@smart_patients" property="twitter:site" />
<meta content="https://www.smartpatients.com/smart-patients-logo-200.png" property="twitter:image" />
<script>window.gon = {};gon.browser={"os":null,"platform":null,"browser":"SiteSucker","version":""};gon.selection=null;gon.privileges=[];</script>
<meta content="authenticity_token" name="csrf-param" />
<meta content="anHdzK0RV47A1fm+Cc5YWchDmz7Dd1CW3v8C5VSfjds=" name="csrf-token" />
<title>PD-1 | Smart Patients</title>
<!--[if lt IE 10]>
<script src='https://html5shim.googlecode.com/svn/trunk/html5.js'></script>
<![endif]-->
<link href="../assets/application-d023587940a25f1311fac7be224dde01.css" media="all" rel="stylesheet" type="text/css" />
<link href="../assets/print/print-791dc2f04757964770191d5c923539c6.css" media="print" rel="stylesheet" type="text/css" />

<!--[if lt IE 10]>
<link href="/assets/ie/ie-fb3a9d11af866d1ad554b557627df8f6.css" media="all" rel="stylesheet" type="text/css" />
<![endif]-->
<!--[if lt IE 9]>
<link href="/assets/ie/ie8-b1f4d1991397313b50b84b7d76d6ba05.css" media="all" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="https://fonts.googleapis.com/css?family=Handlee%7CBitter:400,700" rel="stylesheet" type="text/css" />

</head>

<body class='not-logged-in'>
<script id='tag_template' type='text/x-handlebars-template'>
<p>
{{{description}}}
</p>
<p class='status_{{tag_name}}'></p>
<p class='tag_link'>
<img alt="Icon_favorite_selected" src="/assets/icon_favorite_selected-37a484115fc7df83408fabd97664140b.png" />
{{{follow_link}}}
</p>
<img alt="Spinner" class="spinner hidden" src="/assets/spinner-3f3b3866a7fa212b261a33db16ecbaf5.gif" />
<div class='topic-count'>
<a href='{{tag_path}}'>
{{{count}}}
</a>
</div>
</script>

<script id='interest_template' type='text/x-handlebars-template'>
<li class='interest' data-interest-id='{{id}}'>
<div class='outer'>
<div class='inner'>
{{{url}}}
{{{remove_link}}}
</div>
</div>
</li>
</script>

<script id='alert_template' type='text/x-handlebars-template'>
<div class='alert {{class}}'>
<button aria-hidden='true' class='close' data-dismiss='alert' type='button'>
x
</button>
<p>
{{message}}
</p>
</div>
</script>

<script id='alert_template_html' type='text/x-handlebars-template'>
<div class='alert {{class}}'>
<button aria-hidden='true' class='close' data-dismiss='alert' type='button'>
x
</button>
<p>
{{{message}}}
</p>
</div>
</script>

<script id='profile_popup_template' type='text/x-handlebars-template'><pre class='profile_popup'>{{ profile }}</pre><div class='instructions'>
{{ instructions }}
</div>
</script>

<script id='survey_rating_results_template' type='text/x-handlebars-template'>
<div class='rating-result'>
<div>
{{message}}
</div>
<div>
Your rating: {{user_rating}}
</div>
<div>
Average: {{average}}
</div>
<div>
Total # of votes: {{count}}
</div>
</div>
</script>

<script id='target_details_template' type='text/x-handlebars-template'>
<p>
{{name}} <span class="pill {{node_type}}">{{node_type}}</span>
<ul>
{{#each neighbors}}
<li>
{{this.name}} <span class="pill {{this.node_type}}">{{this.node_type}}</span>
</li>
{{/each}}
</ul>
</p>
</script>

<script id='trial_contact_message' type='text/x-handlebars-template'>
I'm interested in "{{{brief_title}}}"
Trial ID: {{trial_id}}
{{institution}}
{{address}}
Thank you in advance for contacting me to discuss this trial.
</script>

<script id='featured_quote_template' type='text/x-handlebars-template'>
<div class='testimonial quoted-snippet'>
{{trimString quote 250}}
</div>
{{#if attribution}}
<div class='signed'>
– {{attribution}}
</div>
{{/if}}
</script>


<div class='container'>
<div class='navbar'>
<div class='navbar-inner'>
<div class='clearfix'>
<div class='row'>
<a href="../index.html" class="brand"><img alt="Smart-patients-logo-350" height="69" src="../assets/smart-patients-logo-350-bb0285894b87daf2798d6c0a81d0c51b.png" style="height: 69px" width="350" /></a>
<ul class='nav'>
</ul>
<div class='mini-signin-link'>
<a href="../signin.html">sign in</a>
</div>
<div class='signin_container pull-right'>
<div class='error' id='login_status'></div>
<form accept-charset="UTF-8" action="/sessions" class="form-inline login" data-remote="true" id="signin_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="anHdzK0RV47A1fm+Cc5YWchDmz7Dd1CW3v8C5VSfjds=" /></div>
<div class='control-group'>
<div class='controls'><input class="login required ezpz" id="email" name="email" placeholder="Email" tabindex="1" type="email" /></div>
</div>
<div class='control-group'>
<div class='controls'>
<input class="login required ezpz" id="password" maxlength="20" minlength="6" name="password" placeholder="Password" tabindex="2" type="password" />
</div>
</div>
<div class='control-group'>
<div class='controls'>
<input class="btn btn-small" id="signin_btn" name="commit" tabindex="3" type="submit" value="Sign in" />
</div>
</div>
<div class='clearfix'></div>
<div class='control-group remember-me'>
<div class='controls'>
<label for='remember_me'>
<input id="remember_me" name="remember_me" tabindex="4" type="checkbox" value="1" />
keep me signed in
</label>
</div>
</div>
<div class='forgotpass-div'>
<a href="../forgot_password.html" class="forgot-password pull-right" tabindex="5">Forgot password?</a>
</div>
</form>

</div>


</div>
</div>
</div>
</div>
</div>

<div class='container' data-title='PD-1 | Smart Patients' id='page'>
<div class='row'>
<div class='span2'></div>
<div class='span10 divider main'>
<div class='row'>
<div class='span7 messages'>

</div>
</div>
</div>
</div>
<div class='row'>
<div class='span12 divider main'>
<div class='row'>
<div class='span9 right-divider'>
<script id='trial_popover_template' type='text/x-handlebars-template'>
<ul>
{{ds}}
{{#each trials}}
<li>
{{#if this.link}}
<a class='trial_widget_links' data-intervention='{{../../../intervention}}' data-trial-id='{{this.id}}' href='{{this.link}}' target='_blank'>
{{this.id}}
{{#if this.text}}
({{this.text}})
{{/if}}
</a>
{{else}}
{{#if ../../source}}
<a href='/clinical-trials/{{this.id}}?source={{../../source}}' target='_blank'></a>
{{else}}
<a class='trial_widget_links' data-intervention='{{../../../intervention}}' data-trial-id='{{this.id}}' href='/clinical-trials/{{this.id}}' target='_blank'>
{{/if}}
{{this.id}}
{{#if this.text}}
({{this.text}})
{{/if}}
</a>
{{/if}}
<p>
{{trimString this.title 120}}
</p>
</li>
{{/each}}
</ul>
</script>


<div id='content-page'>
<div class='content-title'>
<h1>Cancer Immunology: PD-1 and Beyond</h1>
</div>
<div class='content-main'>
<h3>
Overview
</h3>
<p>
Immunotherapy, or more specifically, the use of monoclonal antibodies that block inhibitory immune checkpoint molecules to enhance the immune response to tumors, has shown clinical promise in advanced solid tumors. Therapies in this category include PD-1, PD-L1, CTLA-4, IDO pathway blockers (hereafter collectively described as PD-1 inhibitors). There are many other checkpoint proteins that we will not be discussing in detail, but will include as “other checkpoint inhibitors” in the table below.
</p>
<p>
PD-1 inhibitors are an exciting new category of immunotherapy drugs which may provide new treatment options for multiple types of cancers, such as melanoma, non-small cell lung cancer and kidney cancer, all of which are currently being studied in clinical trials. This is probably just the beginning though, as many other cancers will likely be good candidates for PD-1 inhibitors, which harness the power of the immune system to mount an anti-cancer attack.
</p>
<div class='image'>
<img alt="PD-1 pathway" height="293" src="../assets/pd1/pd1-pathway-916d9130b5f1418bfe30c15cf178627e.png" width="800" />
</div>
<p>
Our immune system’s T cells can kill cancer cells. However, T cells are tightly regulated (or held under control) to avoid autoimmune reactions. Many cancers have evolved to hijack these built in controls to keep T cells from killing cancer cells. T cells have a protein on their surface called PD-1 (in orange above). When PD-1 binds to PD-L1 (yellow) on another cell, the T cell becomes deactivated. Most cancer cells have PD-L1 on their surface and escape being killed by turning off the T cell in this way.
</p>
<p>
Anti-PD-1 antibodies (dark green) or anti-PD-L1 antibodies (light green) can prevent the tumor cell from binding PD-1 and thus allow T cells to remain active. These are the “PD-1 inhibitors” that are currently being tested in clinical trials. See below for more details about T cells and PD-1.
</p>
<h3>PD-1 Clinical Trials</h3>
<table class='pd-1' data-condition-name='PD-1' id='trial-widget'>
<tr>
<th>
<div class='condition_name'>
PD-1
</div>
</th>
<th>
<div class='big'>
94
</div>
<div class='th_label'>
phase 1
</div>
</th>
<th>
<div class='big'>
106
</div>
<div class='th_label'>
phase 2
</div>
</th>
<th>
<div class='big'>
26
</div>
<div class='th_label'>
phase 3
</div>
</th>
<th>
<div class='big'>
18
</div>
<div class='th_label'>
other*
</div>
</th>
<th>
<div class='big'>
244
</div>
<div class='th_label'>total</div>
</th>
</tr>
<tr class="subheader_0"><td colspan="6">PD-1</td></tr><tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MEDI0680</span><div class="synonyms">AMP-514</div><em class="manufacturer">AstraZeneca</em><td class="on phases" data-content-name="pd-1" data-intervention="MEDI0680" data-phase="phase1" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02013804&quot;,&quot;title&quot;:&quot;A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="pd-1" data-intervention="MEDI0680" data-phase="phase2" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td data-content-name="pd-1" data-intervention="MEDI0680" data-phase="phase3" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td data-content-name="pd-1" data-intervention="MEDI0680" data-phase="other" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="pd-1" data-intervention="MEDI0680" data-phase="all" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02013804&quot;,&quot;title&quot;:&quot;A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Pidilizumab</span><div class="synonyms">CT-011</div><em class="manufacturer">Teva</em><td data-content-name="pd-1" data-intervention="Pidilizumab" data-phase="phase1" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="pd-1" data-intervention="Pidilizumab" data-phase="phase2" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01067287&quot;,&quot;title&quot;:&quot;Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01420965&quot;,&quot;title&quot;:&quot;Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01441765&quot;,&quot;title&quot;:&quot;PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01952769&quot;,&quot;title&quot;:&quot;Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma and Relapsed Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02077959&quot;,&quot;title&quot;:&quot;Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01313416&quot;,&quot;title&quot;:&quot;Gemcitabine and CT-011 for Resected Pancreatic Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00904722&quot;,&quot;title&quot;:&quot;Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01096602&quot;,&quot;title&quot;:&quot;Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">8</td><td data-content-name="pd-1" data-intervention="Pidilizumab" data-phase="phase3" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td data-content-name="pd-1" data-intervention="Pidilizumab" data-phase="other" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="pd-1" data-intervention="Pidilizumab" data-phase="all" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01067287&quot;,&quot;title&quot;:&quot;Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01420965&quot;,&quot;title&quot;:&quot;Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01441765&quot;,&quot;title&quot;:&quot;PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01952769&quot;,&quot;title&quot;:&quot;Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma and Relapsed Glioblastoma Multiforme&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02077959&quot;,&quot;title&quot;:&quot;Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01313416&quot;,&quot;title&quot;:&quot;Gemcitabine and CT-011 for Resected Pancreatic Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT00904722&quot;,&quot;title&quot;:&quot;Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01096602&quot;,&quot;title&quot;:&quot;Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">8</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Pembralizumab</span><div class="synonyms">Keytruda, MK-3475</div><em class="manufacturer">Merck</em><td class="on phases" data-content-name="pd-1" data-intervention="Pembralizumab" data-phase="phase1" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02212730&quot;,&quot;title&quot;:&quot;A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01295827&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01840579&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Monotherapy in Participants With Advanced Solid Tumors and Pembrolizumab Combination Therapy in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02036502&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02180061&quot;,&quot;title&quot;:&quot;Study of MK-3475 (Pembrolizumab) in Participants With Advanced Melanoma (MK-3475-041)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02054806&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02007070&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01848834&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01953692&quot;,&quot;title&quot;:&quot;A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02179918&quot;,&quot;title&quot;:&quot;A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02014636&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02179918&quot;,&quot;title&quot;:&quot;A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02112032&quot;,&quot;title&quot;:&quot;Treatment of Advanced Melanoma With MK-3475 and Peginterferon&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">13</td><td class="on phases" data-content-name="pd-1" data-intervention="Pembralizumab" data-phase="phase2" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02089685&quot;,&quot;title&quot;:&quot;Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01704287&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02130466&quot;,&quot;title&quot;:&quot;A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02178722&quot;,&quot;title&quot;:&quot;A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02129556&quot;,&quot;title&quot;:&quot;Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">6</td><td class="on phases" data-content-name="pd-1" data-intervention="Pembralizumab" data-phase="phase3" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02220894&quot;,&quot;title&quot;:&quot;Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02142738&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01905657&quot;,&quot;title&quot;:&quot;Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01866319&quot;,&quot;title&quot;:&quot;Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02142738&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">5</td><td class="on phases" data-content-name="pd-1" data-intervention="Pembralizumab" data-phase="other" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02083484&quot;,&quot;title&quot;:&quot;Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)&quot;,&quot;phase&quot;:&quot;other&quot;}]">1</td><td class="on phases" data-content-name="pd-1" data-intervention="Pembralizumab" data-phase="all" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02083484&quot;,&quot;title&quot;:&quot;Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02212730&quot;,&quot;title&quot;:&quot;A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01295827&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01840579&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Monotherapy in Participants With Advanced Solid Tumors and Pembrolizumab Combination Therapy in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02036502&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02180061&quot;,&quot;title&quot;:&quot;Study of MK-3475 (Pembrolizumab) in Participants With Advanced Melanoma (MK-3475-041)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02054806&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02007070&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01848834&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01953692&quot;,&quot;title&quot;:&quot;A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02179918&quot;,&quot;title&quot;:&quot;A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02014636&quot;,&quot;title&quot;:&quot;Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02179918&quot;,&quot;title&quot;:&quot;A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02112032&quot;,&quot;title&quot;:&quot;Treatment of Advanced Melanoma With MK-3475 and Peginterferon&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02089685&quot;,&quot;title&quot;:&quot;Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01704287&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02130466&quot;,&quot;title&quot;:&quot;A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02178722&quot;,&quot;title&quot;:&quot;A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02129556&quot;,&quot;title&quot;:&quot;Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02220894&quot;,&quot;title&quot;:&quot;Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02142738&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01905657&quot;,&quot;title&quot;:&quot;Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01866319&quot;,&quot;title&quot;:&quot;Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02142738&quot;,&quot;title&quot;:&quot;Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">25</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Nivolumab</span><div class="synonyms">BMS-936558, MDX-1106</div><em class="manufacturer">Bristol-Myers Squibb</em><td class="on phases" data-content-name="pd-1" data-intervention="Nivolumab" data-phase="phase1" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT00730639&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01472081&quot;,&quot;title&quot;:&quot;Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01621490&quot;,&quot;title&quot;:&quot;PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01024231&quot;,&quot;title&quot;:&quot;Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01592370&quot;,&quot;title&quot;:&quot;Safety Study of Nivolumab and Ipilimumab in Hematologic Malignancy&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01176474&quot;,&quot;title&quot;:&quot;A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01658878&quot;,&quot;title&quot;:&quot;Dose Escalation Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC) With or Without Chronic Viral Hepatitis&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01714739&quot;,&quot;title&quot;:&quot;A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02011945&quot;,&quot;title&quot;:&quot;A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01358721&quot;,&quot;title&quot;:&quot;Phase I Biomarker Study (BMS-936558)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01968109&quot;,&quot;title&quot;:&quot;Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01176461&quot;,&quot;title&quot;:&quot;Multiple Class I Peptides \u0026 Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00836888&quot;,&quot;title&quot;:&quot;ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01629758&quot;,&quot;title&quot;:&quot;Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">15</td><td class="on phases" data-content-name="pd-1" data-intervention="Nivolumab" data-phase="phase2" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01354431&quot;,&quot;title&quot;:&quot;BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02210117&quot;,&quot;title&quot;:&quot;Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01927419&quot;,&quot;title&quot;:&quot;Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma (CheckMate 069)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01928394&quot;,&quot;title&quot;:&quot;A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01721759&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens (CheckMate 063)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02156804&quot;,&quot;title&quot;:&quot;A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02060188&quot;,&quot;title&quot;:&quot;A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02017717&quot;,&quot;title&quot;:&quot;A Randomized Study of Nivolumab or Nivolumab Combined With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma(GBM)(CheckMate 143)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02038946&quot;,&quot;title&quot;:&quot;Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02181738&quot;,&quot;title&quot;:&quot;Study of Nivolumab in Subjects With Hodgkin&#x27;s Lymphoma (Registrational) (CheckMate 205)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02038933&quot;,&quot;title&quot;:&quot;Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01783938&quot;,&quot;title&quot;:&quot;Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02175017&quot;,&quot;title&quot;:&quot;ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01928576&quot;,&quot;title&quot;:&quot;Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">14</td><td class="on phases" data-content-name="pd-1" data-intervention="Nivolumab" data-phase="phase3" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01642004&quot;,&quot;title&quot;:&quot;Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01844505&quot;,&quot;title&quot;:&quot;Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01673867&quot;,&quot;title&quot;:&quot;Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate 057)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02224781&quot;,&quot;title&quot;:&quot;Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02066636&quot;,&quot;title&quot;:&quot;A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01721746&quot;,&quot;title&quot;:&quot;A Study to Compare BMS-936558 to the Physician&#x27;s Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01668784&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01721772&quot;,&quot;title&quot;:&quot;Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma (CheckMate 066)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02041533&quot;,&quot;title&quot;:&quot;An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator&#x27;s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02231749&quot;,&quot;title&quot;:&quot;Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02105636&quot;,&quot;title&quot;:&quot;Trial of Nivolumab vs Therapy of Investigator&#x27;s Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">11</td><td class="on phases" data-content-name="pd-1" data-intervention="Nivolumab" data-phase="other" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02186249&quot;,&quot;title&quot;:&quot;Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy\u00ae) in Anti-CTLA-4 Treatment-Na\u00efve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02142218&quot;,&quot;title&quot;:&quot;Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti_CTLA-4 Monoclonal Antibody (CheckMate 168)&quot;,&quot;phase&quot;:&quot;other&quot;}]">2</td><td class="on phases" data-content-name="pd-1" data-intervention="Nivolumab" data-phase="all" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02186249&quot;,&quot;title&quot;:&quot;Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy\u00ae) in Anti-CTLA-4 Treatment-Na\u00efve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02142218&quot;,&quot;title&quot;:&quot;Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti_CTLA-4 Monoclonal Antibody (CheckMate 168)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00730639&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01472081&quot;,&quot;title&quot;:&quot;Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01621490&quot;,&quot;title&quot;:&quot;PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01024231&quot;,&quot;title&quot;:&quot;Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01592370&quot;,&quot;title&quot;:&quot;Safety Study of Nivolumab and Ipilimumab in Hematologic Malignancy&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01176474&quot;,&quot;title&quot;:&quot;A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01658878&quot;,&quot;title&quot;:&quot;Dose Escalation Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC) With or Without Chronic Viral Hepatitis&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01714739&quot;,&quot;title&quot;:&quot;A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02011945&quot;,&quot;title&quot;:&quot;A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01358721&quot;,&quot;title&quot;:&quot;Phase I Biomarker Study (BMS-936558)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01968109&quot;,&quot;title&quot;:&quot;Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01176461&quot;,&quot;title&quot;:&quot;Multiple Class I Peptides \u0026 Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00836888&quot;,&quot;title&quot;:&quot;ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01629758&quot;,&quot;title&quot;:&quot;Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01354431&quot;,&quot;title&quot;:&quot;BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02210117&quot;,&quot;title&quot;:&quot;Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01927419&quot;,&quot;title&quot;:&quot;Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma (CheckMate 069)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01928394&quot;,&quot;title&quot;:&quot;A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01721759&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens (CheckMate 063)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02156804&quot;,&quot;title&quot;:&quot;A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02060188&quot;,&quot;title&quot;:&quot;A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02017717&quot;,&quot;title&quot;:&quot;A Randomized Study of Nivolumab or Nivolumab Combined With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma(GBM)(CheckMate 143)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02038946&quot;,&quot;title&quot;:&quot;Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02181738&quot;,&quot;title&quot;:&quot;Study of Nivolumab in Subjects With Hodgkin&#x27;s Lymphoma (Registrational) (CheckMate 205)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02038933&quot;,&quot;title&quot;:&quot;Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01783938&quot;,&quot;title&quot;:&quot;Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02175017&quot;,&quot;title&quot;:&quot;ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01928576&quot;,&quot;title&quot;:&quot;Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01642004&quot;,&quot;title&quot;:&quot;Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01844505&quot;,&quot;title&quot;:&quot;Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01673867&quot;,&quot;title&quot;:&quot;Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate 057)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02224781&quot;,&quot;title&quot;:&quot;Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02066636&quot;,&quot;title&quot;:&quot;A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01721746&quot;,&quot;title&quot;:&quot;A Study to Compare BMS-936558 to the Physician&#x27;s Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01668784&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01721772&quot;,&quot;title&quot;:&quot;Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma (CheckMate 066)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02041533&quot;,&quot;title&quot;:&quot;An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator&#x27;s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02231749&quot;,&quot;title&quot;:&quot;Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02105636&quot;,&quot;title&quot;:&quot;Trial of Nivolumab vs Therapy of Investigator&#x27;s Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">42</td></td></tr>
<tr class="subheader_0"><td colspan="6">PD-L1</td></tr><tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MEDI4736</span><em class="manufacturer">AstraZeneca</em><td class="on phases" data-content-name="pd-1" data-intervention="MEDI4736" data-phase="phase1" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01938612&quot;,&quot;title&quot;:&quot;A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Japanese Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02117219&quot;,&quot;title&quot;:&quot;Phase 1 Study to Evaluate MEDI4736&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02088112&quot;,&quot;title&quot;:&quot;MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01693562&quot;,&quot;title&quot;:&quot;A Phase 1 Study to Evaluate MEDI4736&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02000947&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02118337&quot;,&quot;title&quot;:&quot;A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01975831&quot;,&quot;title&quot;:&quot;A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02141347&quot;,&quot;title&quot;:&quot;A Phase I Study to Assess the Safety, Tolerability of Tremelimumab and Tremelimumab in Combination With MEDI4736 in Japanese Patients With Advanced Solid Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">9</td><td class="on phases" data-content-name="pd-1" data-intervention="MEDI4736" data-phase="phase2" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02027961&quot;,&quot;title&quot;:&quot;Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02087423&quot;,&quot;title&quot;:&quot;A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02227667&quot;,&quot;title&quot;:&quot;Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02207530&quot;,&quot;title&quot;:&quot;Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02205333&quot;,&quot;title&quot;:&quot;A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">6</td><td class="on phases" data-content-name="pd-1" data-intervention="MEDI4736" data-phase="phase3" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02125461&quot;,&quot;title&quot;:&quot;A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td data-content-name="pd-1" data-intervention="MEDI4736" data-phase="other" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="pd-1" data-intervention="MEDI4736" data-phase="all" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01938612&quot;,&quot;title&quot;:&quot;A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Japanese Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02117219&quot;,&quot;title&quot;:&quot;Phase 1 Study to Evaluate MEDI4736&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02088112&quot;,&quot;title&quot;:&quot;MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01693562&quot;,&quot;title&quot;:&quot;A Phase 1 Study to Evaluate MEDI4736&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02143466&quot;,&quot;title&quot;:&quot;AZD9291 in Combination With Ascending Doses of Novel Therapeutics&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02000947&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02118337&quot;,&quot;title&quot;:&quot;A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01975831&quot;,&quot;title&quot;:&quot;A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02141347&quot;,&quot;title&quot;:&quot;A Phase I Study to Assess the Safety, Tolerability of Tremelimumab and Tremelimumab in Combination With MEDI4736 in Japanese Patients With Advanced Solid Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02027961&quot;,&quot;title&quot;:&quot;Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02087423&quot;,&quot;title&quot;:&quot;A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02227667&quot;,&quot;title&quot;:&quot;Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02207530&quot;,&quot;title&quot;:&quot;Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN.&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02205333&quot;,&quot;title&quot;:&quot;A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02125461&quot;,&quot;title&quot;:&quot;A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02154490&quot;,&quot;title&quot;:&quot;Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">17</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">MPDL3280A</span><em class="manufacturer">Genentech</em><td class="on phases" data-content-name="pd-1" data-intervention="MPDL3280A" data-phase="phase1" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02013219&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Tarceva in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02174172&quot;,&quot;title&quot;:&quot;A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01656642&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf\u00ae) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01633970&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02220842&quot;,&quot;title&quot;:&quot;A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01988896&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01375842&quot;,&quot;title&quot;:&quot;A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">7</td><td class="on phases" data-content-name="pd-1" data-intervention="MPDL3280A" data-phase="phase2" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01984242&quot;,&quot;title&quot;:&quot;A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02108652&quot;,&quot;title&quot;:&quot;A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01846416&quot;,&quot;title&quot;:&quot;A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - \&quot;FIR\&quot;&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02031458&quot;,&quot;title&quot;:&quot;A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - \&quot;BIRCH\&quot;&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01903993&quot;,&quot;title&quot;:&quot;A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \&quot;POPLAR\&quot;&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">5</td><td class="on phases" data-content-name="pd-1" data-intervention="MPDL3280A" data-phase="phase3" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02008227&quot;,&quot;title&quot;:&quot;A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \&quot;OAK\&quot;&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">1</td><td data-content-name="pd-1" data-intervention="MPDL3280A" data-phase="other" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="pd-1" data-intervention="MPDL3280A" data-phase="all" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02013219&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Tarceva in Patients With Non-Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02174172&quot;,&quot;title&quot;:&quot;A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01656642&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf\u00ae) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01633970&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02220842&quot;,&quot;title&quot;:&quot;A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01988896&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01375842&quot;,&quot;title&quot;:&quot;A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01984242&quot;,&quot;title&quot;:&quot;A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02108652&quot;,&quot;title&quot;:&quot;A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01846416&quot;,&quot;title&quot;:&quot;A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - \&quot;FIR\&quot;&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02031458&quot;,&quot;title&quot;:&quot;A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - \&quot;BIRCH\&quot;&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01903993&quot;,&quot;title&quot;:&quot;A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \&quot;POPLAR\&quot;&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02008227&quot;,&quot;title&quot;:&quot;A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \&quot;OAK\&quot;&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">13</td></td></tr>
<tr class="subheader_0"><td colspan="6">CTLA-4</td></tr><tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Ipilimumab</span><div class="synonyms">Yervoy, MDX-010, MDX-011</div><em class="manufacturer">Bristol-Myers Squibb</em><td class="on phases" data-content-name="pd-1" data-intervention="Ipilimumab" data-phase="phase1" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01621490&quot;,&quot;title&quot;:&quot;PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01750983&quot;,&quot;title&quot;:&quot;Ipilimumab and Lenalidomide in Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01472081&quot;,&quot;title&quot;:&quot;Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01738139&quot;,&quot;title&quot;:&quot;Ipilimumab and Imatinib Mesylate in Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01860430&quot;,&quot;title&quot;:&quot;A Phase Ib Trial of Concurrent Cetuximab (ERBITUX\u00ae) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY\u00ae) in Locally Advanced Head and Neck Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01767454&quot;,&quot;title&quot;:&quot;Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01703507&quot;,&quot;title&quot;:&quot;Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02117362&quot;,&quot;title&quot;:&quot;Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01757639&quot;,&quot;title&quot;:&quot;Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01838200&quot;,&quot;title&quot;:&quot;A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01822509&quot;,&quot;title&quot;:&quot;Ipilimumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01711515&quot;,&quot;title&quot;:&quot;Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01935921&quot;,&quot;title&quot;:&quot;Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01810016&quot;,&quot;title&quot;:&quot;NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01896999&quot;,&quot;title&quot;:&quot;Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01998126&quot;,&quot;title&quot;:&quot;Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01729806&quot;,&quot;title&quot;:&quot;Ipilimumab and Rituximab In Treating Patients With Relapsed or Refractory B-Cell Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01940809&quot;,&quot;title&quot;:&quot;Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01473940&quot;,&quot;title&quot;:&quot;Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01643278&quot;,&quot;title&quot;:&quot;Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01592370&quot;,&quot;title&quot;:&quot;Safety Study of Nivolumab and Ipilimumab in Hematologic Malignancy&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01750580&quot;,&quot;title&quot;:&quot;Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01557114&quot;,&quot;title&quot;:&quot;Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02032810&quot;,&quot;title&quot;:&quot;Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01950195&quot;,&quot;title&quot;:&quot;SRS (Stereotactic Radiosurgery) Plus Ipilimumab&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02210104&quot;,&quot;title&quot;:&quot;Adoptive Therapy Using Antigen-Specific CD4 T-Cells&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01984255&quot;,&quot;title&quot;:&quot;A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01176474&quot;,&quot;title&quot;:&quot;A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02077114&quot;,&quot;title&quot;:&quot;Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02174172&quot;,&quot;title&quot;:&quot;A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02070406&quot;,&quot;title&quot;:&quot;Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00586391&quot;,&quot;title&quot;:&quot;CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin&#x27;s Lymphoma, ALL \u0026 CLL&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01996202&quot;,&quot;title&quot;:&quot;A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">34</td><td class="on phases" data-content-name="pd-1" data-intervention="Ipilimumab" data-phase="phase2" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01565837&quot;,&quot;title&quot;:&quot;Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01689974&quot;,&quot;title&quot;:&quot;Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01323517&quot;,&quot;title&quot;:&quot;Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01740297&quot;,&quot;title&quot;:&quot;Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01708941&quot;,&quot;title&quot;:&quot;Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01585194&quot;,&quot;title&quot;:&quot;Ipilimumab for Uveal Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01827111&quot;,&quot;title&quot;:&quot;Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02196961&quot;,&quot;title&quot;:&quot;Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy\u00ae) Versus Observation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02113657&quot;,&quot;title&quot;:&quot;T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02020070&quot;,&quot;title&quot;:&quot;Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01590082&quot;,&quot;title&quot;:&quot;Doxycycline, Temozolomide and Ipilimumab in Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02073123&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01950390&quot;,&quot;title&quot;:&quot;Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02107755&quot;,&quot;title&quot;:&quot;Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02210117&quot;,&quot;title&quot;:&quot;Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01498978&quot;,&quot;title&quot;:&quot;Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01331525&quot;,&quot;title&quot;:&quot;The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02203604&quot;,&quot;title&quot;:&quot;High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01693783&quot;,&quot;title&quot;:&quot;Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01530984&quot;,&quot;title&quot;:&quot;Ipilimumab and GMCSF Immunotherapy for Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01970527&quot;,&quot;title&quot;:&quot;Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01688492&quot;,&quot;title&quot;:&quot;Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na\u00efve Patients With Progressive Metastatic Castration-resistant Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02158520&quot;,&quot;title&quot;:&quot;Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01820754&quot;,&quot;title&quot;:&quot;Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01879306&quot;,&quot;title&quot;:&quot;Abraxane Plus Bevacizumab Versus Ipilimumab as 1st Line Therapy for BRAFwt Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02046733&quot;,&quot;title&quot;:&quot;Small Cell Lung Cancer Trial With IpiliMUmab in LImited Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01896869&quot;,&quot;title&quot;:&quot;A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01988077&quot;,&quot;title&quot;:&quot;Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02054520&quot;,&quot;title&quot;:&quot;Immunotherapy Study for Patients With Stage IV Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02221739&quot;,&quot;title&quot;:&quot;Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01928394&quot;,&quot;title&quot;:&quot;A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01783938&quot;,&quot;title&quot;:&quot;Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01409174&quot;,&quot;title&quot;:&quot;IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02115139&quot;,&quot;title&quot;:&quot;GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01216696&quot;,&quot;title&quot;:&quot;Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01804465&quot;,&quot;title&quot;:&quot;A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02027935&quot;,&quot;title&quot;:&quot;Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696045&quot;,&quot;title&quot;:&quot;Phase 2 Study of Ipilimumab in Children and Adolescents (12 to \u003C 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02017717&quot;,&quot;title&quot;:&quot;A Randomized Study of Nivolumab or Nivolumab Combined With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma(GBM)(CheckMate 143)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02097732&quot;,&quot;title&quot;:&quot;Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01604889&quot;,&quot;title&quot;:&quot;A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02094391&quot;,&quot;title&quot;:&quot;Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02060188&quot;,&quot;title&quot;:&quot;A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01524991&quot;,&quot;title&quot;:&quot;First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02115243&quot;,&quot;title&quot;:&quot;Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02009397&quot;,&quot;title&quot;:&quot;A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02200562&quot;,&quot;title&quot;:&quot;Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02009384&quot;,&quot;title&quot;:&quot;Study of Ipilimumab Administered to Stage IIIC and Stage IV Melanoma Patients After Regulatory T Cell Depletion With Denileukin Diftitox&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01480323&quot;,&quot;title&quot;:&quot;A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 in Pretreated Patients With Stage IV Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02089685&quot;,&quot;title&quot;:&quot;Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01497808&quot;,&quot;title&quot;:&quot;RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01973608&quot;,&quot;title&quot;:&quot;MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">53</td><td class="on phases" data-content-name="pd-1" data-intervention="Ipilimumab" data-phase="phase3" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02224781&quot;,&quot;title&quot;:&quot;Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01274338&quot;,&quot;title&quot;:&quot;Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01450761&quot;,&quot;title&quot;:&quot;Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02231749&quot;,&quot;title&quot;:&quot;Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01285609&quot;,&quot;title&quot;:&quot;Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">5</td><td class="on phases" data-content-name="pd-1" data-intervention="Ipilimumab" data-phase="other" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01919619&quot;,&quot;title&quot;:&quot;Lenalidomide and Ipilimumab Post Allo or Auto Stem Cell Transplantation (SCT)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01608594&quot;,&quot;title&quot;:&quot;Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-\u03b12b for Melanoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01701674&quot;,&quot;title&quot;:&quot;Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01856023&quot;,&quot;title&quot;:&quot;HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02050594&quot;,&quot;title&quot;:&quot;Ipilimumab 12-month Intensive Pharmacovigilance Protocol&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02068196&quot;,&quot;title&quot;:&quot;A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01449279&quot;,&quot;title&quot;:&quot;Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02186249&quot;,&quot;title&quot;:&quot;Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy\u00ae) in Anti-CTLA-4 Treatment-Na\u00efve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01715077&quot;,&quot;title&quot;:&quot;Study of Ipilimumab in the Immune System&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02224768&quot;,&quot;title&quot;:&quot;YERVOY\u00ae Risk Minimization Tool Effectiveness Evaluation Survey&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01789827&quot;,&quot;title&quot;:&quot;Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab Therapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01511913&quot;,&quot;title&quot;:&quot;A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02083484&quot;,&quot;title&quot;:&quot;Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00685750&quot;,&quot;title&quot;:&quot;Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01758575&quot;,&quot;title&quot;:&quot;Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities&quot;,&quot;phase&quot;:&quot;other&quot;}]">15</td><td class="on phases" data-content-name="pd-1" data-intervention="Ipilimumab" data-phase="all" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01919619&quot;,&quot;title&quot;:&quot;Lenalidomide and Ipilimumab Post Allo or Auto Stem Cell Transplantation (SCT)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01608594&quot;,&quot;title&quot;:&quot;Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-\u03b12b for Melanoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01701674&quot;,&quot;title&quot;:&quot;Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01856023&quot;,&quot;title&quot;:&quot;HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02050594&quot;,&quot;title&quot;:&quot;Ipilimumab 12-month Intensive Pharmacovigilance Protocol&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02068196&quot;,&quot;title&quot;:&quot;A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01449279&quot;,&quot;title&quot;:&quot;Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02186249&quot;,&quot;title&quot;:&quot;Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy\u00ae) in Anti-CTLA-4 Treatment-Na\u00efve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01715077&quot;,&quot;title&quot;:&quot;Study of Ipilimumab in the Immune System&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02224768&quot;,&quot;title&quot;:&quot;YERVOY\u00ae Risk Minimization Tool Effectiveness Evaluation Survey&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01789827&quot;,&quot;title&quot;:&quot;Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab Therapy&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01511913&quot;,&quot;title&quot;:&quot;A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT02083484&quot;,&quot;title&quot;:&quot;Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT00685750&quot;,&quot;title&quot;:&quot;Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01758575&quot;,&quot;title&quot;:&quot;Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities&quot;,&quot;phase&quot;:&quot;other&quot;},{&quot;id&quot;:&quot;NCT01621490&quot;,&quot;title&quot;:&quot;PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01750983&quot;,&quot;title&quot;:&quot;Ipilimumab and Lenalidomide in Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01472081&quot;,&quot;title&quot;:&quot;Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01738139&quot;,&quot;title&quot;:&quot;Ipilimumab and Imatinib Mesylate in Advanced Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01860430&quot;,&quot;title&quot;:&quot;A Phase Ib Trial of Concurrent Cetuximab (ERBITUX\u00ae) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY\u00ae) in Locally Advanced Head and Neck Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01767454&quot;,&quot;title&quot;:&quot;Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01703507&quot;,&quot;title&quot;:&quot;Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02117362&quot;,&quot;title&quot;:&quot;Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01757639&quot;,&quot;title&quot;:&quot;Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01838200&quot;,&quot;title&quot;:&quot;A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01822509&quot;,&quot;title&quot;:&quot;Ipilimumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01711515&quot;,&quot;title&quot;:&quot;Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01935921&quot;,&quot;title&quot;:&quot;Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01810016&quot;,&quot;title&quot;:&quot;NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01896999&quot;,&quot;title&quot;:&quot;Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01998126&quot;,&quot;title&quot;:&quot;Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01729806&quot;,&quot;title&quot;:&quot;Ipilimumab and Rituximab In Treating Patients With Relapsed or Refractory B-Cell Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01940809&quot;,&quot;title&quot;:&quot;Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01473940&quot;,&quot;title&quot;:&quot;Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01643278&quot;,&quot;title&quot;:&quot;Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01592370&quot;,&quot;title&quot;:&quot;Safety Study of Nivolumab and Ipilimumab in Hematologic Malignancy&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01750580&quot;,&quot;title&quot;:&quot;Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01557114&quot;,&quot;title&quot;:&quot;Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02032810&quot;,&quot;title&quot;:&quot;Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01950195&quot;,&quot;title&quot;:&quot;SRS (Stereotactic Radiosurgery) Plus Ipilimumab&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02210104&quot;,&quot;title&quot;:&quot;Adoptive Therapy Using Antigen-Specific CD4 T-Cells&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01454102&quot;,&quot;title&quot;:&quot;Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01984255&quot;,&quot;title&quot;:&quot;A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01176474&quot;,&quot;title&quot;:&quot;A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02077114&quot;,&quot;title&quot;:&quot;Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02174172&quot;,&quot;title&quot;:&quot;A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02070406&quot;,&quot;title&quot;:&quot;Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT00586391&quot;,&quot;title&quot;:&quot;CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin&#x27;s Lymphoma, ALL \u0026 CLL&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01996202&quot;,&quot;title&quot;:&quot;A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01565837&quot;,&quot;title&quot;:&quot;Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01689974&quot;,&quot;title&quot;:&quot;Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01323517&quot;,&quot;title&quot;:&quot;Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01740297&quot;,&quot;title&quot;:&quot;Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01708941&quot;,&quot;title&quot;:&quot;Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01585194&quot;,&quot;title&quot;:&quot;Ipilimumab for Uveal Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01827111&quot;,&quot;title&quot;:&quot;Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02196961&quot;,&quot;title&quot;:&quot;Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy\u00ae) Versus Observation&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02113657&quot;,&quot;title&quot;:&quot;T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02020070&quot;,&quot;title&quot;:&quot;Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01590082&quot;,&quot;title&quot;:&quot;Doxycycline, Temozolomide and Ipilimumab in Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02073123&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01950390&quot;,&quot;title&quot;:&quot;Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02107755&quot;,&quot;title&quot;:&quot;Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02210117&quot;,&quot;title&quot;:&quot;Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01498978&quot;,&quot;title&quot;:&quot;Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01331525&quot;,&quot;title&quot;:&quot;The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02203604&quot;,&quot;title&quot;:&quot;High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01693783&quot;,&quot;title&quot;:&quot;Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01530984&quot;,&quot;title&quot;:&quot;Ipilimumab and GMCSF Immunotherapy for Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01970527&quot;,&quot;title&quot;:&quot;Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01688492&quot;,&quot;title&quot;:&quot;Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na\u00efve Patients With Progressive Metastatic Castration-resistant Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02158520&quot;,&quot;title&quot;:&quot;Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01820754&quot;,&quot;title&quot;:&quot;Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01879306&quot;,&quot;title&quot;:&quot;Abraxane Plus Bevacizumab Versus Ipilimumab as 1st Line Therapy for BRAFwt Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02046733&quot;,&quot;title&quot;:&quot;Small Cell Lung Cancer Trial With IpiliMUmab in LImited Disease&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01896869&quot;,&quot;title&quot;:&quot;A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01988077&quot;,&quot;title&quot;:&quot;Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02054520&quot;,&quot;title&quot;:&quot;Immunotherapy Study for Patients With Stage IV Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02221739&quot;,&quot;title&quot;:&quot;Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01928394&quot;,&quot;title&quot;:&quot;A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01783938&quot;,&quot;title&quot;:&quot;Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01409174&quot;,&quot;title&quot;:&quot;IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02115139&quot;,&quot;title&quot;:&quot;GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01216696&quot;,&quot;title&quot;:&quot;Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01804465&quot;,&quot;title&quot;:&quot;A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02027935&quot;,&quot;title&quot;:&quot;Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01696045&quot;,&quot;title&quot;:&quot;Phase 2 Study of Ipilimumab in Children and Adolescents (12 to \u003C 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02017717&quot;,&quot;title&quot;:&quot;A Randomized Study of Nivolumab or Nivolumab Combined With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma(GBM)(CheckMate 143)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02097732&quot;,&quot;title&quot;:&quot;Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01604889&quot;,&quot;title&quot;:&quot;A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02094391&quot;,&quot;title&quot;:&quot;Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02060188&quot;,&quot;title&quot;:&quot;A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01524991&quot;,&quot;title&quot;:&quot;First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02115243&quot;,&quot;title&quot;:&quot;Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02009397&quot;,&quot;title&quot;:&quot;A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02200562&quot;,&quot;title&quot;:&quot;Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02009384&quot;,&quot;title&quot;:&quot;Study of Ipilimumab Administered to Stage IIIC and Stage IV Melanoma Patients After Regulatory T Cell Depletion With Denileukin Diftitox&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01480323&quot;,&quot;title&quot;:&quot;A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 in Pretreated Patients With Stage IV Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02089685&quot;,&quot;title&quot;:&quot;Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01497808&quot;,&quot;title&quot;:&quot;RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02039674&quot;,&quot;title&quot;:&quot;A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01973608&quot;,&quot;title&quot;:&quot;MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02224781&quot;,&quot;title&quot;:&quot;Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01274338&quot;,&quot;title&quot;:&quot;Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01450761&quot;,&quot;title&quot;:&quot;Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT02231749&quot;,&quot;title&quot;:&quot;Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01285609&quot;,&quot;title&quot;:&quot;Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">107</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Tremelimumab</span><div class="synonyms">CP-675,206</div><em class="manufacturer">MedImmune/Pfizer</em><td class="on phases" data-content-name="pd-1" data-intervention="Tremelimumab" data-phase="phase1" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02000947&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02040064&quot;,&quot;title&quot;:&quot;Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">2</td><td class="on phases" data-content-name="pd-1" data-intervention="Tremelimumab" data-phase="phase2" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02205333&quot;,&quot;title&quot;:&quot;A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01843374&quot;,&quot;title&quot;:&quot;Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01655888&quot;,&quot;title&quot;:&quot;The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">4</td><td data-content-name="pd-1" data-intervention="Tremelimumab" data-phase="phase3" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td data-content-name="pd-1" data-intervention="Tremelimumab" data-phase="other" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="pd-1" data-intervention="Tremelimumab" data-phase="all" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02000947&quot;,&quot;title&quot;:&quot;A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02040064&quot;,&quot;title&quot;:&quot;Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02179671&quot;,&quot;title&quot;:&quot;Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02205333&quot;,&quot;title&quot;:&quot;A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01843374&quot;,&quot;title&quot;:&quot;Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01655888&quot;,&quot;title&quot;:&quot;The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">6</td></td></tr>
<tr class="subheader_0"><td colspan="6">IDO Inhibitors</td></tr><tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">Indoximod</span><em class="manufacturer">NewLink Genetics</em><td data-content-name="pd-1" data-intervention="Indoximod" data-phase="phase1" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="pd-1" data-intervention="Indoximod" data-phase="phase2" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01792050&quot;,&quot;title&quot;:&quot;Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01560923&quot;,&quot;title&quot;:&quot;Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02077881&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02073123&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02052648&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">5</td><td data-content-name="pd-1" data-intervention="Indoximod" data-phase="phase3" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td data-content-name="pd-1" data-intervention="Indoximod" data-phase="other" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="pd-1" data-intervention="Indoximod" data-phase="all" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01792050&quot;,&quot;title&quot;:&quot;Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01560923&quot;,&quot;title&quot;:&quot;Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02077881&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02073123&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT02052648&quot;,&quot;title&quot;:&quot;Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">5</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">NLG919</span><em class="manufacturer">NewLink Genetics</em><td class="on phases" data-content-name="pd-1" data-intervention="NLG919" data-phase="phase1" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02048709&quot;,&quot;title&quot;:&quot;IDO Inhibitor Study for Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td><td data-content-name="pd-1" data-intervention="NLG919" data-phase="phase2" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td data-content-name="pd-1" data-intervention="NLG919" data-phase="phase3" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td data-content-name="pd-1" data-intervention="NLG919" data-phase="other" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="pd-1" data-intervention="NLG919" data-phase="all" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02048709&quot;,&quot;title&quot;:&quot;IDO Inhibitor Study for Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">1</td></td></tr>
<tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">INCBO24360</span><em class="manufacturer">NewLink Genetics</em><td data-content-name="pd-1" data-intervention="INCBO24360" data-phase="phase1" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="pd-1" data-intervention="INCBO24360" data-phase="phase2" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02178722&quot;,&quot;title&quot;:&quot;A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01604889&quot;,&quot;title&quot;:&quot;A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td><td data-content-name="pd-1" data-intervention="INCBO24360" data-phase="phase3" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td data-content-name="pd-1" data-intervention="INCBO24360" data-phase="other" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="pd-1" data-intervention="INCBO24360" data-phase="all" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT02178722&quot;,&quot;title&quot;:&quot;A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01604889&quot;,&quot;title&quot;:&quot;A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">2</td></td></tr>
<tr class="subheader_0"><td colspan="6">Other Immune Checkpoint Inhibitors</td></tr><tr><td><img alt="drug" height="24" src="../assets/icon-drug-0c68f329db13ef6d376226f3041ecf4f.png" width="24" /><span class="intervention">IMP321, MGA271, Lirilumab,  Urelumab, BMS-986016, Bavituximab, Racotumomab</span><em class="manufacturer"></em><td class="on phases" data-content-name="pd-1" data-intervention="IMP321, MGA271, Lirilumab,  Urelumab, BMS-986016, Bavituximab, Racotumomab" data-phase="phase1" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01918930&quot;,&quot;title&quot;:&quot;Tissue Procurement Substudy for Participants in Study CP-MGA271-01&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01391143&quot;,&quot;title&quot;:&quot;Safety Study of MGA271 in Refractory Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01714739&quot;,&quot;title&quot;:&quot;A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01750580&quot;,&quot;title&quot;:&quot;Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01471210&quot;,&quot;title&quot;:&quot;Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin&#x27;s Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01775631&quot;,&quot;title&quot;:&quot;Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLL&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02110082&quot;,&quot;title&quot;:&quot;Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01968109&quot;,&quot;title&quot;:&quot;Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02061761&quot;,&quot;title&quot;:&quot;Safety Study of Anti-LAG-3 in CLL, HL and NHL&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01634685&quot;,&quot;title&quot;:&quot;A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01323062&quot;,&quot;title&quot;:&quot;Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01984255&quot;,&quot;title&quot;:&quot;A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;}]">12</td><td class="on phases" data-content-name="pd-1" data-intervention="IMP321, MGA271, Lirilumab,  Urelumab, BMS-986016, Bavituximab, Racotumomab" data-phase="phase2" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01308294&quot;,&quot;title&quot;:&quot;Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01687387&quot;,&quot;title&quot;:&quot;Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01264705&quot;,&quot;title&quot;:&quot;Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;}]">3</td><td class="on phases" data-content-name="pd-1" data-intervention="IMP321, MGA271, Lirilumab,  Urelumab, BMS-986016, Bavituximab, Racotumomab" data-phase="phase3" data-placement="bottom" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01999673&quot;,&quot;title&quot;:&quot;Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01460472&quot;,&quot;title&quot;:&quot;Immunotherapy With Racotumomab in Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">2</td><td data-content-name="pd-1" data-intervention="IMP321, MGA271, Lirilumab,  Urelumab, BMS-986016, Bavituximab, Racotumomab" data-phase="other" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[]">0</td><td class="on phases" data-content-name="pd-1" data-intervention="IMP321, MGA271, Lirilumab,  Urelumab, BMS-986016, Bavituximab, Racotumomab" data-phase="all" data-placement="bottom_left" data-popup-id="pd-1" data-source="null" data-trials="[{&quot;id&quot;:&quot;NCT01918930&quot;,&quot;title&quot;:&quot;Tissue Procurement Substudy for Participants in Study CP-MGA271-01&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01391143&quot;,&quot;title&quot;:&quot;Safety Study of MGA271 in Refractory Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01714739&quot;,&quot;title&quot;:&quot;A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01750580&quot;,&quot;title&quot;:&quot;Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01471210&quot;,&quot;title&quot;:&quot;Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin&#x27;s Lymphoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01775631&quot;,&quot;title&quot;:&quot;Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLL&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02110082&quot;,&quot;title&quot;:&quot;Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01968109&quot;,&quot;title&quot;:&quot;Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT02061761&quot;,&quot;title&quot;:&quot;Safety Study of Anti-LAG-3 in CLL, HL and NHL&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01634685&quot;,&quot;title&quot;:&quot;A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01323062&quot;,&quot;title&quot;:&quot;Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01984255&quot;,&quot;title&quot;:&quot;A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients&quot;,&quot;phase&quot;:&quot;phase1&quot;},{&quot;id&quot;:&quot;NCT01308294&quot;,&quot;title&quot;:&quot;Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01687387&quot;,&quot;title&quot;:&quot;Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01264705&quot;,&quot;title&quot;:&quot;Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer&quot;,&quot;phase&quot;:&quot;phase2&quot;},{&quot;id&quot;:&quot;NCT01999673&quot;,&quot;title&quot;:&quot;Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;},{&quot;id&quot;:&quot;NCT01460472&quot;,&quot;title&quot;:&quot;Immunotherapy With Racotumomab in Advanced Lung Cancer&quot;,&quot;phase&quot;:&quot;phase3&quot;}]">17</td></td></tr>
</table>
<p>
*
<em>Phase 4 or compassionate care study</em>
<br>
**
<em>Only ongoing studies are included (recruiting, pending recruitment or active, but not yet recruiting)</em>
</p>
<p>
<a href="../contact-subject=The+PD-1+trial+table+is+missing+a+trial&trial_table=PD-1.html" rel="nofollow">Are we missing a trial?</a>
</p>
<div class='popover-div' id='pd-1'></div>

<h3>
PD-1 Details
</h3>
<p>
PD-1 inhibitors are a kind of “immunotherapy” and to see how they work, let’s look at a key part of our immune system: the T cell. T cells are part of our natural defense system. They can kill infected cells and cells that aren't working properly, like cancer cells. T cells require two separate signals to be turned on or activated -- like requiring two keys to be turned simultaneously to prevent accidental launch of a weapon. This tight regulation helps prevent T cells from attacking normal cells and causing overly aggressive immune reactions. Cancer cells exploit this safety mechanism by blocking one of the two keys and thus keeping the T cell inactivated.
</p>
<p>
When the immune system is working correctly, cells called antigen-presenting cells or APCs normally provide the two keys (signals) that activate two receptors on the T cells. One key on the APC’s surface is a small protein originally from an infected or cancerous cell, referred to as an antigen, which fits into the T cell receptor on the T cell’s surface. The other key is a molecule called B7 on the APC that binds to another receptor (lock) on the T cell called CD28.
</p>
<p>
Again, activating the T cell requires that the antigen bind the T cell receptor AND that B7 bind to CD28. Once these two keys are in these two locks, the T-cell is activated and can seek out and destroy infected cells or cancer cells.
</p>
<h3>
Cancer Immunology in Action
</h3>
<p>
There are multiple immune-checkpoint receptors on the T cell (not just CD28), all working together, or against each other.  To name just two, CTLA-4 and PD-1 receptors also have roles in cancer immunology.
</p>
<p>
The T cell itself can prevent one of the keys from doing its job in order to “keep the brakes on” the immune system. A receptor called CTLA-4 on the T cell can bind B7 on the APC, which means B7 cannot bind CD28 and the T cell is not activated. For example, a drug called ipilimumab (brand name Yervoy), is an antibody that binds to CLTA-4, keeps CTLA-4 from binding B7, allows B7 to bind CD28, and restores the two signals the T cell needs to remain activated. The drug may act as an outside key to lock the CTLA-4 pathway, allowing CD28 to be the sole lock for the B7 key.
</p>
<p>
Another receptor on the T cell, called PD-1, provides one more checkpoint to help make sure T cells don’t cause too much damage to normal cells. However, the T cell can be fully turned off, or deactivated, when PD-1 is bound by its counterpart on the APC, PD-L1 (L is for ligand). Normally, when an activated T cell finds a cancer cell, it can kill it once it binds to the same antigen on the cancer cell’s surface that the APC showed the T cell when it was activated. However, most cancer cells have PD-L1 on their surface and escape by turning off the T cell in this way.
</p>
<p>
For example, there are several antibodies in clinical trials that bind to and therefore block either PD-1 or PD-L1 to prevent this "turn off" signal that happens when PD-L1 on the cancer cell binds to PD-1 on the T cell. As a result, T cells are able to kill the cancer cells.
</p>
</div>
</div>

</div>
<div class='span3 sidebar no-padding-or-margin'>

<div class='widget '>
<div class='invitation-widget'>
<h2>Join the conversation!</h2>
<form accept-charset="UTF-8" action="/users" class="signup form-inline" id="new_user" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="anHdzK0RV47A1fm+Cc5YWchDmz7Dd1CW3v8C5VSfjds=" /></div><div class='join-button'>
<input class="btn btn-primary join-btn" name="commit" type="submit" value="Join Now" />
</div>
<div class="control-group required"><div class="controls"><input class="email required ezpz" id="invitation_email" name="user[email]" placeholder="Enter your email address" required="required" size="30" type="text" /></div></div>
<div class="notice"><p>If you're not a patient or caregiver, <a href="../contact-subject=Joining+Smart+Patients.html">click here</a>.</p></div>
<div class='notice'>
<p class='already-a-member'>Already a member? <a href="../signin.html">Sign in</a>.</p>
</div>
<input id="community" name="community" type="hidden" value="" />
<input id="partner" name="partner" type="hidden" value="" />
<input id="tags" name="tags" type="hidden" value="PD-1" />
<input id="return_url" name="return_url" type="hidden" value="/pathways/pd-1" />
<div class='controls request-button'>
<input class="btn btn-primary join-btn" name="commit" type="submit" value="Join Now" />
</div>
<div class='clearfix'></div>
</form>
</div>


<hr>
</div>


</div>
</div>
</div>
</div>
</div>
<div class='footer_background_container'>
<div class='footer_background'></div>
</div>
<div id='fat_footer'>
<div class='container'>
<footer class='row'>
<ul>
<li class='title'>
Links
</li>
<li>
<a href='../signin.html' title='Smart Patients - Home'>Conversations</a>
</li>
<li>
<a href='../stories.html' title='Stories'>Stories</a>
</li>
<li>
<a href='../quotes.html' title='Quotes recommended by members of the Smart Patients community.'>Quotes</a>
</li>
<li>
<a href='../trials.html' title='Search for clinical trials'>Clinical Trials</a>
</li>
</ul>
<ul>
<li class='title'>
Resources
</li>
<li>
<a href='../tutorial.html' title='Tutorial'>Tutorial</a>
</li>
<li>
<a href='../glossary.html' title='Tutorial'>Glossary</a>
</li>
<li>
<a href='../faq.html' title='Frequently asked questions'>FAQ</a>
</li>
</ul>
<ul>
<li class='title'>
Company
</li>
<li>
<a href='../about.html' title='About'>About</a>
</li>
<li>
<a href='../terms.html' title='Terms of Agreement'>Terms</a>
</li>
<li>
<a href='../privacy.html' title='Privacy Statement'>Privacy</a>
</li>
<li>
<a href='../contact.html' title='Contact Us'>Contact Us</a>
</li>
</ul>
<ul>
<li class='title'>
Social
</li>
<li>
<a href='../voices.html' title='Community Voices'>
<img alt="Icon_community_voices" src="../assets/icon_community_voices-51b928126bf735b2f04e9c969184afe3.png" />
Community Voices
</a>
</li>
<li>
<a href='../blog/index.html' title='Smart Patients Blog'>
<img alt="Icon_rss" src="../assets/icon_rss-16f5922fc759195730036b4454ef43a9.png" />
Smart Patients Blog
</a>
</li>
<li>
<a href='https://twitter.com/smart_patients' target='_blank' title='Twitter'>
<img alt="Icon_twitter" src="../assets/icon_twitter-5f7dbcc5d175199272b25b76fdda7dcd.png" />
Twitter
</a>
</li>
<li>
<a href='https://www.facebook.com/pages/Smart-Patients/393175704082838' target='_blank' title='Facebook'>
<img alt="Icon_facebook" src="../assets/icon_facebook-bb0ca36aa4757152d61004e0595d2e50.png" />
Facebook
</a>
</li>
</ul>
</footer>
<div class='copyright'>&copy;2015 Smart Patients, Inc., all rights reserved
</div>
<div class='creative_commons'>
<a href="../creative_commons.html">some icons</a>
are licensed under the Creative Commons license.
</div>
</div>
</div>

<script>
  var _gaq = _gaq || [];
  _gaq.push(['_setAccount', "UA-33347034-1"]);
  _gaq.push(['_setDomainName', 'smartpatients.com']);
  _gaq.push(['_trackPageview']);
  
  _gaq.push(['_setCustomVar',
    1,
    'logged_in',
    "false",
    2 // session-level
  ]);
  (function() {
    var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
    ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
  })();
</script>


<script src="../assets/application-6488ad0d66b77f64bcc10cde7b8e3212.js" type="text/javascript"></script>
<script src="../assets/jquery.hoverIntent.minified-3948fb0a36bb799e79553266985a1b22.js" type="text/javascript"></script>
<script src="../assets/jquery.validate.min-639617c1797dd4f18f2e40348e222928.js" type="text/javascript"></script>
<script src="../assets/jquery.cookie-108e498e814a1dbb62f1c6a88c61db48.js" type="text/javascript"></script>
<!--[if lt IE 10]>  <![endif]-->
<script src="../assets/jquery.placeholder.min-635ef1b648831ce3225097bb831210ca.js" type="text/javascript"></script>
<script>
  (function() {
    var root;
  
    root = typeof exports !== "undefined" && exports !== null ? exports : this;
  
    if ($('.wmd-input').length === 1) {
      root.converter = Markdown.getSanitizingConverter();
      root.converter.hooks.chain("preConversion", function(text) {
        text = text.replace(/^https?:\/\/[a-z0-9\.:]+(\/forums\/1-conversations\/topics\/[0-9]+-.*$)/mgi, "[Title of linked conversation will appear here]($1)");
        text = text.replace(/^(NCT[0-9]{8})$/mgi, "[Title for '$1' will appear here](/trials/$1)");
        text = text.replace(/:-\)/g, '☺');
        text = text.replace(/:-\(/g, '☹');
        text = text.replace(/:flower:/g, '⚘');
        text = text.replace(/:heart:/g, '❤');
        text = text.replace(/:star:/g, '★');
        text = text.replace(/:rose:/g, '❀');
        text = text.replace(/:music:/g, '♫');
        return text.replace(/(^|[\s\(])(NCT[0-9]{8})($|[\s\)])/gi, "$1[$2](/trials/$2)$3");
      });
      root.editor = new Markdown.Editor(converter);
      root.editor.run();
    }
  
  }).call(this);
</script>




</body>
</html>
